GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

In 2020, the FDA instructed all companies to take Zantac off the market after it confirmed that the medicine’s main ingredient can transform into a possible carcinogen over time or when exposed ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

as well as GSK — to pull Zantac off the market over mounting concerns that its active ingredient, ranitidine, could degrade into an organic chemical called NDMA, over time or when exposed to heat.

GlaxoSmithKline agreed on Sept. 17 to settle out of the first Zantac trial in California, which began this month in Oakland. GSK won two defense verdicts in Illinois earlier this year but faced ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was “no consistent or reliable evidence” that ranitidine, the drug’s active ingredient, increased the risk ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...